Posts

J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout

on

Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on

on

Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production

on

FDA's Shock Rejection of Ebvallo Cell Therapy: Reconsideration Efforts and uniQure Concerns

on

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

on

UCB Acquires Neurona Therapeutics for Up to $1.15B to Advance Epilepsy Cell Therapy

on

FDA Extends Orca Bio Orca-T Review Timeline Following Manufacturing Data Submission

on

Oryon Cell Therapies Emerges With $42M for Autologous Neuron Replacement Therapy in Parkinson's Disease

on

AstraZeneca Announces Cell Therapy Manufacturing Hub and R&D Center in Shanghai

on

Unixell Biotech Receives FDA IND Clearance for UX-GIP001 iPSC-Derived Cell Therapy for Focal Epilepsy

on

MindWalk Announces B Cell Llama, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

on

Orca Bio Presents Clinical Data on High-Precision Cell Therapies at 52nd EBMT Annual Meeting

on

Gilead Sciences Acquires Arcellx in $7.8 Billion Deal to Control CAR-T Cell Therapy

on

Johnson & Johnson Announces Over $1 Billion Investment in Pennsylvania Cell Therapy Facility

on

AstraZeneca Announces $15 Billion Investment in China Through 2030

on

Novo Offloads Cell Therapy Technologies to Aspect After Retreat from the Field

on

Spotlight On: Five key oncology stories to watch in 2026

on

Kyverna to seek FDA engagement after positive autoimmune CAR-T data in stiff person syndrome

on

China’s fast, low-cost gene and cell therapy testing boom draws Western interest

on

Spotlight On: Big Pharma's Big Bets on In Vivo Cell Therapy

on